Get Permission Sugathan, Abraham, Thomas, Paily, and John: Hymenal tag; a clue to the diagnosis of vaginal polyp: A case report of primary vaginal melanoma mimicking an undifferentiated pleomorphic sarcoma


Introduction

Primary malignant melanoma of the vagina is a rare and aggressive malignancy with a high risk of local recurrence and distant metastasis.

It accounts for less than 0.3% of all melanomas and approximately 4% of vaginal malignancies. 1, 2 Most of the patients are post-menopausal with a mean age of around 60 years. The most common symptom is vaginal bleeding followed by vaginal mass and discharge. The tumour mass is usually located in the anterior and lateral walls of the lower third of the vaginal wall. Macroscopically most are polypoidal or nodular, with an average size of 2-3 cms. Most of the cases are pigmented while a few are amelanotic 3, 4, 5 The unusual phenotypic profiles of melanomas, including those that mimic the non- melanocytic lineage, may pose a diagnostic challenge. Here we present a case report and literature review of a case of primary vaginal malignant melanoma, the morphology of which mimicked an undifferentiated pleomorphic sarcoma. The clue to diagnosis came from a hymenal mucosal tag specimen of the same patient which showed classical features of malignant melanoma.

Case Report

A 61-year-old female presented to the gynaecology outpatient department of our hospital, with complaints of difficulty in urination, increased frequency of micturition, and a polyp arising from the vagina. 

Clinical history 

She gave a history of total abdominal hysterectomy 20 years back for fibroid uterus. There was no history of malignancy in the family.

Local examination 

On examination, a pedunculated swelling of 5x3 cm arising from the lateral vaginal wall, at 2 o’clock position close to the hymenal remnant and extending to the suburethral region was identified. A mucosal tag, measuring 6x4 mm was noted at 8 o’clock position; protruding from the hymenal remnant. There were no palpable inguinal lymph nodes.

Investigations

Preoperative ultrasonogram confirmed the presence of a heterogeneous lesion with internal vascularity in the lateral vaginal wall, of possibly neoplastic etiology.

Microscopy

Vaginal polyp and hymenal tag were excised and sent for histopathology. Microscopically, the vaginal polyp showed an infiltrating neoplasm composed of pleomorphic cells with hyperchromatic/vesicular nuclei and bizarre multinucleate giant cells. The neoplasm showed ulceration of the overlying stratified squamous epithelium. Histopathological examination of the hymenal tag, showed atypical melanocytes with intracytoplasmic brownish-black pigment, exhibiting a lentiginous pattern of growth along the base of the lining epithelium and infiltrating the underlying connective tissue. This gave the clue to the diagnosis of malignant melanoma in the vaginal polyp. The neoplastic cells in the vaginal polyp were strongly positive for S100 and HMB45 immunostains; thereby confirming the diagnosis.

The patient underwent PET-CT for staging which showed randomly distributed lung parenchymal nodules suspicious for pulmonary metastasis. No lymph nodal metastasis was identified.

Figure 1

Gross and Microscopy images. A: Vaginal polyp gross photograph, arrow-hymenal pigmented tag; B: Hymenal tag microscopy 100x, H&E. shows nests of tumour cells in the epithelium and subepithelial tissue; C: Hymenal tag microscopy 4 00x, H&E, Tumour cells showing intracytoplasmic brownish black pigment; D: Vaginal polyp, H&E 400X, shows bizzare multinucleated giant cells; E: Immunohistochemistry HMB 45 on vaginal polyp 400x, Shows strong membranous and cytoplasmic positivity in the neoplastic cells; F: Immunohistochemistry S100 on vaginal polyp 400x. Shows strong nuclear and cytoplasmic positivity in the neoplastic cells

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/28e9f849-dbc4-4b28-a425-864b3dc30f1e/image/f3cf238a-21bc-4c9f-b977-41ce5328775e-uimage.png

Discussion

Melanoma is a malignancy that most commonly arises in the sun-exposed regions of the trunk and extremities. The lower extremities are the commonest site in women. The melanomas occurring in the female genital tract are biologically aggressive and account for 3% to 7% of all melanomas. The first case of malignant melanoma of the female genital tract was reported by Hewitt in 1861.1 The most common site for gynecologic melanomas is the vulva. Around 85% of cases arise in the labia minora, clitoris, or inner side of the labia majora.2 

Melanocytes are seen as embryological remnants of neural crest cells in three percent of healthy women. The aforesaid melanocytes beget primary malignant melanoma of the vagina.3  Little is known about the risk factors, etiological factors, and the pathogenesis of these tumors.4

Vaginal melanomas usually present in the fifth to seventh decades of life. Most of the cases are seen in the lower one-third of the anterior vaginal wall. Typically,patients with vaginal melanoma experience a prodrome of vaginal bleeding (80%) vaginal discharge(25%), palpable mass(15%) in the vagina, and pain (10%).5 

Vaginal melanomas have a polypoid to nodular macroscopic appearance in the majority of cases. Although a predominant number of these neoplasms are pigmented, 10%–23% are amelanotic.6  The amelanotic vaginal polyp, in our case, would have caused much diagnostic confusion, if not for the pigmented hymenal tag; which makes our case noteworthy.

Vaginal melanomas have a poor prognosis. Early local recurrence, lymph node involvement, and distant metastasis are common. This might be due to the rich vascular and lymphatic network of the vaginal mucosa and a delay in diagnosis can be detrimental for the patient.5, 7, 8

Tumor size of more than 3 cm is the most important prognostic factor. Buchanan et al.9 reported that tumors with a diameter of less than 3 cm carry a better prognosis. The stage of the disease and the histopathological variant also play a role in prognosis. Our patient had a tumor size of more than 3 cm, causing concern for dismal prognosis. Most of the vaginal melanomas are aggressive in nature and tend to be diagnosed at late stages with a 5-year survival rate of 0%–25%; and this dwindles to 5% in 3 years with lymph node involvement.3 Tumor thickness and increased dermal mitotic rate (≥2/mm2) were independent predictors for reduced survival in vulvar melanoma.10

Several treatment options are advocated, but none of them are considered to be a standard approach. Surgical resection is considered to be the first choice as improved overall survival has been demonstrated in patients treated with surgery when compared to those treated exclusively with chemoradiation.11, 12 The gamut of surgical options range from conservative surgery such as wide local excision with lymph node dissection to total vaginectomy or radical extirpation with en bloc removal of the involved pelvic organs.13 Excision with conservative margins of 1cm for tumors that are 1mm thick or less, 2cm for those 1–4mm thick with a minimum 1cm tumor-free deep margin are the current recommended standards.13, 14 Nevertheless, a significant difference in survival between patients who have radical surgical procedures and those who have more conservative surgical procedures have not been demonstrated. 

Neoadjuvant treatment with chemotherapy or radiotherapy has been used in vaginal melanoma to reduce tumor burden enabling a more conservative resection.15 Radiation therapy is indicated in surgically nonresectable disease, pathologically positive margins or metastatic nodes. Adjuvant systemic therapy is indicated in these high-risk cases.16  Biochemotherapy is considered as a systemic option for advanced and metastatic vulvovaginal melanomas.17  Nivolumab (a programmed death-1 (PD-1) immune checkpoint inhibitor) alone or combined with ipilimumab seemed to have greater efficacy than either agent alone, in the treatment of vaginal melanomas.18  Our patient was lost to follow up after surgical excision of the tumor.

Conclusion

Malignant melanoma of the vagina is a rare and aggressive disease affecting women in the 6th and 7th decades of life. The varying phenotypic profile, both gross and microscopy, can lead to an alternate or late diagnosis, which can have an impact on the prognosis of the disease. Hence a high index of suspicion should be maintained by clinicians and pathologists to avoid diagnostic pitfalls.

Source of Funding

None.

Conflict of Interest

None.

References

1 

P Hewitt Sequel to a case of recurrent melanosis of both groins and back: The disease reappearing in the brain, heart, pancreas, liver and other organLancet Oncol2008997381

2 

C J Dunton D Berd Vulvar melanoma, biologically different from other cutaneous melanomasLancet1999354919520134

3 

E Kalampokas T Kalampokas C Damaskos Primary Vaginal Melanoma, A Rare and Aggressive Entity. A Case Report and Review of the LiteratureIn Vivo20173111339

4 

G Androutsopoulos E Terzakis G Ioannidou A Tsamandas G Decavalas Vaginal Primary Malignant Melanoma: A Rare and Aggressive TumorCase Rep Obstet Gynecol2013201316

5 

T J Miner R Delgado J Zeisler Primary vaginal melanoma: a critical analysis of therapyAnn Surg Oncol2004111349

6 

S Chaudhuri S Chowdhury D Das A D Gupta Primary malignant melanoma of the vagina: A case report and review of literatureS Asian J Cancer2013214

7 

G C Reid R W Schmidt J A Roberts M P Hopkins R J Barrett G W Morley Primary melanoma of the vagina: a clinicopathologic analysisObstet Gynecol19897421909

8 

B Piura A Rabinovich I Yanai-Inbar Primary malignant melanoma of the vagina: case report and review of literatureEur J Gynaecol Oncol20022331958

9 

D J Buchanan J Schlaerth T Kurosaki Primary vaginal melanoma: Thirteen-year disease-free survival after wide local excision and review of recent literatureAm J Obstet Gynecol19981786117784

10 

P Nagarajan J L Curry J Ning Tumor thickness and mitotic rate robustly predict melanoma-specific survival in patients with primary vulvar melanoma: A retrospective review of 100 casesClin Cancer Res2017232093104

11 

M Frumovitz M Etchepareborda C C Sun P T Soliman P J Eifel C F Levenback Primary Malignant Melanoma of the VaginaObstet Gynecol20101166135865

12 

M Frumovitz M Etchepareborda C C Sun P T Soliman P J Eifel C F Levenback Primary Malignant Melanoma of the VaginaObstet Gynecol20101166135865

13 

B Piura Management of primary melanoma of the female urogenital tractLancet Oncol200891097381

14 

L A Kottschade T E Grotz R S Dronca D R Salomao J S Pulido N Wasif Rare Presentations of Primary Melanoma and Special PopulationsAm J Clin Oncol201437663541

15 

J M T Janco S N Markovic A L Weaver W A. Cliby Vulvar and vaginal melanoma: Case series and review of current management options including neoadjuvant chemotherapyGynecol Oncol201312935337

16 

V E Sugiyama J K Chan D S Kapp Management of melanomas of the female genital tractCurr Opin Oncol20082055659

17 

M S Harting K B Kim Biochemotherapy in patients with advanced vulvovaginal mucosal melanomaMelanoma Res200414651720

18 

S P D'Angelo J Larkin J A Sosman C Lebbé B Brady B Neyns Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled AnalysisJ Clin Oncol20173522635



jats-html.xsl


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

  • Article highlights
  • Article tables
  • Article images

View Article

PDF File   Full Text Article


Copyright permission

Get article permission for commercial use

Downlaod

PDF File   XML File   ePub File


Digital Object Identifier (DOI)

Article DOI

https://doi.org/10.18231/j.ijpo.2020.131


Article Metrics






Article Access statistics

Viewed: 6393

PDF Downloaded: 711